Biological medicines, including biosimilar medicines, contain one or more active substances that are derived from living cells or organisms. Biosimilar medicines are highly similar, but not identical, versions of an already registered biological medicine (the reference biological medicine). This is because the inherent variability of the biological systems used in the manufacturing process means that the resulting product is also variable.
So, are there more adverse effects with the biosimilar medicines? Are there more immunogenic reactions with the biosimilar medicine? On April 1st, BRENZYS was listed on the PBS, join us for this lecture to find out what biosimilars are all about and answer some of these questions. This lecture is presented by Associate Professor David Newby.
SHPA & NHVPA members, please call the PSA office to register 02 9431 1100 or email us at email@example.com or NHVPA members register through www.nhvpa.org.au
Presented by Associate Professor DAVID NEWBY.
THIS IS A ONE HOUR LECTURE!